Net sales declined 13.3% year-over-year due to currency headwinds and lower instrument sales, but gross margin improved to 40.9% on a favorable product mix. Veterinary and OEM segments showed resilience, and the company expects improved sales in the second half of 2026.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.